Home Archives 2008 December

Monthly Archives: December 2008

The January 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 15, Issue 1

Editorial

Biotechnology commercialisation: Getting past the technology-pushPDF
Yali Friedman

Articles

Record integrity and licensing your intellectual propertyPDF
John Avellanet
NIH assistance for new therapeutic development: NIH-RAID Pilot ProgramPDF
David G Badman
Parallel imports: Towards a flexible uniform international rulePDF
Stefan M Miller
Pharmaceutical patents after KSR: What is not obvious?PDF
Jason Lief, Peter Schuyler
ATMP in practice: Towards a new industry landscape in tissue engineeringPDF
Laure Brévignon-Dodin, Pawanbir Singh
Thailand biotech business: Product of the national policyPDF
Nataporn Chanvarasuth, Ramjitti Indaraprasirt

From the Classroom

Teaming in biotechnology commercialisation: The diversity-performance connection and how university programmes can make a differencePDF
Anne S York, Kim A McCarthy, Todd C Darnold

Legal and Regulatory Updates

Legal and regulatory updatePDF
John Wilkinson

Book Reviews

Book Review: Science lessons: What biotech taught me about managementPDF
Arthur A Boni
Book Review: Essentials of pharmacoeconomicsPDF
Harley King

Last week I sent an update to my list of biotech educators about the availability of instructor resources for Building Biotechnology. I’m starting to see interest among educators who I didn’t email, so I ‘m posting a follow-up here to spread the word.

The instructor resources are free for qualified educators and include figures and tables from the text, and sample lectures. Slide decks based on each chapter are also available for a fee, and a quiz bank will be posted shortly.

The instructor resources can be accessed at here, more information on Building Biotechnology is available at here, and the list of schools which have adopted the text is here

Emergent biotechnology companies are very reliant on capital, often having less than two years capital on hand. Like other businesses with strong needs for cash, one would expect biotechnology companies to be adversely effected by a dearth of capital.

The biotechnology financial crisis and request for pass-forward tax breaks have been covered elsewhere; I’ve been looking for stories of who can benefit from the credit crunch.

While at the Mid-Atlantic BIO a few weeks ago I met a banker who seemed buoyed by the credit crisis. He said that the current environment is the first time in over a decade that he’s been in a position to make substantial loans to developing biotechnology companies. He explained that the relative abundance of private equity had previously prevented banks from being able to make loans on profitable terms, but with private equity being far less available, and a substantial federal mandate to make loans in sectors other than real estate, made for a very favorable environment. It’s worth noting, however, that I have yet to see clear evidence that banks are moving en mass into biotech loans.

For a second perspective, I posted a query regarding the impact of the financial crisis on businesses to the Journal of Commercial Biotechnology LinkedIn Group. It is important to note that there’s a strong bias here: individuals who have been displaced and moved to other industries are unlikely to respond, and those still in the industry and facing significant challenges are likewise unlikely to share their troubles publicly. With those biases in mind, the messages on the forum suggested mild changes such as suppliers increasing their vigilence on invoice payment, and hesitation among small and medium firms feeling the pressure of the credit crunch.

A group which stands to benefit from the financial crisis is large companies with strong cash flows. The ethical drug market tends to deliver substantial profits, with many drugs grossing more than $1 billion annually. To support future revenues these companies invest double-digit percentages of revenues in R&D; but they don’t have to. So, these profitable companies may be able to attenuate their R&D expenditures to accomodate fundraising challenges, and likewise license/purchase products from cash-starved development-stage firms at bargain rates. This notion is reinforced in the article, “Still Afloat.”

I’d like to expand my informal survey. Use the comments to answer the question: How is the current financial climate affecting your business?

I’m working on an International Biotechnology ranking and comparison for a well-known publication, and am looking for data sets comparing biotechnology activities in different countries as well as interesting anecdotes about successes/failures/challenges encountered in developing biotechnology in different countries as well between countries. If you’ve got comparative data sets or interesting anecdotes, please drop me a line.

Post your content on BiotechBlog and have it syndicated across the web. Send me a pitch using the contact form.

Guidelines for submissions are:

  • BiotechBlog focuses on commercial, legal, political, and scientific trends in biotechnology. Your post should fit this framework.
  • Posts should be action-oriented (case studies, best practices, guidelines, etc.) or otherwise insightful (perspectives, backgrounders, op-ed’s, etc.) , and not simply rehash press releases or promote commercial services.
  • Please refrain from self-references in the body of posts. You are free to post a byline with a link to your site at the end of articles.
  • You can view other guest content here.

Questions? Use the contact form.